Combining laboratory and computational approaches to develop reliable low cost HIV prognostics [ 2016 - ]

Research Grant

Researchers: Dr Kieran Cashin (Principal investigator)

Brief description Certain anti-HIV drugs called 'CCR5 antagonists' block HIV entry into immune cells. However, HIV drug-resistance can occur. Globally, patient access to CCR5 antagonists has been limited because the pre-treatment laboratory test required to determine HIV drug-resistant is expensive and time-consuming. My research will lead to development of computer programs that reliably, rapidly and cheaply determine HIV drug-resistance and thus greatly improve patient access to CCR5 antagonists worldwide.

Funding Amount $314,644.00

Funding Scheme Early Career Fellowships

Notes Peter Doherty Biomedical ECF